Conv. Plasma
Nigella Sativa
Peg.. Lambda

All remdesivir studies
Meta analysis
Home COVID-19 treatment researchRemdesivirRemdesivir (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality -12% Improvement Relative Risk Remdesivir for COVID-19  Nadeem et al.  LATE TREATMENT Is late treatment with remdesivir beneficial for COVID-19? Retrospective 132 patients in the USA (March 2020 - February 2022) Study underpowered to detect differences Nadeem et al., Cureus, August 2023 Favors remdesivir Favors control

Effects of Different Anticoagulation Doses on Moderate-to-Severe COVID-19 Pneumonia With Hypoxemia

Nadeem et al., Cureus, doi:10.7759/cureus.43389
Aug 2023  
  Source   PDF   All Studies   Meta AnalysisMeta
Retrospective 132 hospitalized COVID-19 patients in the USA, showing no significant difference in mortality with remdesivir in unadjusted results.
Gérard, Wu, Zhou show significantly increased risk of acute kidney injury with remdesivir. This study is excluded in the after exclusion results of meta analysis: unadjusted results with no group details.
risk of death, 12.5% higher, RR 1.12, p = 1.00, treatment 12 of 96 (12.5%), control 4 of 36 (11.1%).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Nadeem et al., 12 Aug 2023, retrospective, USA, peer-reviewed, mean age 59.0, 6 authors, study period 1 March, 2020 - 28 February, 2022.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperRemdesivirAll
Effects of Different Anticoagulation Doses on Moderate-to-Severe COVID-19 Pneumonia With Hypoxemia
Amin Ur Rehman Nadeem, Syed M Naqvi, Kurian G Chandy, Venkata V Nagineni, Rashid Nadeem, Shreya Desai
Cureus, doi:10.7759/cureus.43389
Background COVID-19 is a prothrombotic disease that can cause thromboembolism and microthrombi, which could lead to multiorgan failure and death. Since COVID-19 is a relatively new disease, there are guidelines for anticoagulation dosing for COVID-19 patients without consensus on the dosing. We studied the effects of different doses of anticoagulation in hospitalized patients with COVID-19 pneumonia and hypoxemia on any differences in need for high-flow oxygen, mechanical ventilation, and mortality. We also analyzed the patient population who benefited most from anticoagulation. Methodology We performed a retrospective chart review of all patients who were admitted with the diagnosis of COVID-19 infection with positive polymerase chain reaction, pneumonia (confirmed either by chest X-ray or CT chest), and hypoxemia (oxygen saturation of <94%, while on room air). These patients were studied for outcomes (the need for high-flow oxygen, the requirement for mechanical ventilation, and overall mortality) for different doses of anticoagulation (prophylactic, escalated, and therapeutic). Results The sample consists of 132 subjects, predominantly males (116, 87%), with a mean age of 59 years and a standard deviation of 15. About one-third of the participants had diabetes, and more than 50% had hypertension. Additionally, 27 (20.3%) had a history of heart disease, and 70 (53%) of the subjects were admitted to the intensive care unit (ICU) at some point during the study. Among those admitted to the ICU, about 11 (8%) subjects required mechanical ventilation and 16 (12%) passed away during the study. Those who died had higher use of high-flow oxygen, noninvasive mechanical ventilation, and invasive mechanical ventilation and had a longer stay on mechanical ventilation. There was no significant difference in mortality or need for mechanical ventilation for any strategy of anticoagulation. Conclusions Different doses of anticoagulation did not show any statistically significant relationship between the need for mechanical ventilation and mortality. More patients on high-flow oxygen had received escalated doses of anticoagulation as compared to those who were not on high-flow oxygen. Anticoagulation levels did not have any statistically significant effect on overall survival of patients.
Additional Information Disclosures Human subjects: Consent was obtained or waived by all participants in this study. Edward Hines Jr. Veterans Administration (VA) Hospital, Hines, IL, USA issued approval 21-015. The Institutional Review Board (IRB) committee at Edward Hines Jr. Veterans Administration (VA) Hospital, Hines, IL, USA, approved this study (approval number 21-015). Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.
Al-Samkari, Gupta, Leaf, Thrombosis, bleeding, and the observational effect of early therapeutic anticoagulation on survival in critically ill patients with COVID-19, Ann Intern Med, doi:10.7326/M20-6739?utm_medium=email&utm_source=transaction
Chen, Pan, Anatomical and pathological observation and analysis of SARS and COVID-19: microthrombosis is the main cause of death, Biol Proced Online, doi:10.1186/s12575-021-00142-y?utm_medium=email&utm_source=transaction
Covid-19, Coronavirus Disease 2019 (COVID-19) Treatment Guidelines, National Institutes of Health
Cuker, Tseng, Nieuwlaat, of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: January 2022 update on the use of therapeutic-intensity anticoagulation in acutely ill patients, Blood Adv, doi:10.1182/bloodadvances.2022007561?utm_medium=email&utm_source=transaction
Giorgetti, Orazietti, Busardò, Pirani, Giorgetti, Died with or died of? Development and testing of a SARS CoV-2 significance score to assess the role of COVID-19 in the deaths of affected patients, Diagnostics (Basel), doi:10.3390/diagnostics11020190?utm_medium=email&utm_source=transaction
Henry, Vikse, Benoit, Favaloro, Lippi, Hyperinflammation and derangement of reninangiotensin-aldosterone system in COVID-19: a novel hypothesis for clinically suspected hypercoagulopathy and microvascular immunothrombosis, Clin Chim Acta, doi:10.1016/j.cca.2020.04.027?utm_medium=email&utm_source=transaction
Jhaveri, Meir, Chang, Thrombotic microangiopathy in a patient with COVID-19, Kidney Int, doi:10.1016/j.kint.2020.05.025?utm_medium=email&utm_source=transaction
Jose, Manuel, COVID-19 cytokine storm: the interplay between inflammation and coagulation, Lancet Respir Med, doi:10.1016/S2213-2600(20)30216-2?utm_medium=email&utm_source=transaction
Machhi, Herskovitz, Senan, The natural history, pathobiology, and clinical manifestations of SARS-CoV-2 infections, J Neuroimmune Pharmacol, doi:10.1007/s11481-020-09944-5?utm_medium=email&utm_source=transaction
Meizlish, Goshua, Liu, Intermediate-dose anticoagulation, aspirin, and in-hospital mortality in COVID-19: a propensity score-matched analysis, Am J Hematol, doi:10.1002/ajh.26102?utm_medium=email&utm_source=transaction
Nile, Nile, Qiu, Li, Jia et al., COVID-19: pathogenesis, cytokine storm and therapeutic potential of interferons, Cytokine Growth Factor Rev, doi:10.1016/j.cytogfr.2020.05.002?utm_medium=email&utm_source=transaction
Paranjpe, Fuster, Association of treatment dose anticoagulation with in-hospital survival among hospitalized patients with COVID-19, J Am Coll Cardiol, doi:10.1016/j.jacc.2020.05.001?utm_medium=email&utm_source=transaction
Pei, Yamana, Kandula, Kandula, Galanti et al., Burden and characteristics of COVID-19 in the United States during 2020, Nature, doi:10.1038/s41586-021-03914-4?utm_medium=email&utm_source=transaction
Rapkiewicz, Mai, Carsons, Megakaryocytes and platelet-fibrin thrombi characterize multiorgan thrombosis at autopsy in COVID-19: a case series, EClinicalMedicine, doi:10.1016/j.eclinm.2020.100434?utm_medium=email&utm_source=transaction
Sadeghipour, Talasaz, Rashidi, Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit: the INSPIRATION randomized clinical trial, JAMA, doi:10.1001/jama.2021.4152?utm_medium=email&utm_source=transaction
Santoriello, Khairallah, Bomback, Postmortem kidney pathology findings in patients with COVID-19, J Am Soc Nephrol, doi:10.1681/ASN.2020050744?utm_medium=email&utm_source=transaction
Song, Fitzgerald, COVID-19, microangiopathy, hemostatic activation, and complement, J Clin Invest, doi:10.1172/JCI140183?utm_medium=email&utm_source=transaction
Tacquard, Mansour, Godon, Impact of high-dose prophylactic anticoagulation in critically ill patients with COVID-19 pneumonia, Chest, doi:10.1016/j.chest.2021.01.017?utm_medium=email&utm_source=transaction
Tang, Bai, Chen, Gong, Li et al., Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy, J Thromb Haemost, doi:10.1111/jth.14817?utm_medium=email&utm_source=transaction
Woolf, Chapman, Lee, COVID-19 as the leading cause of death in the United States, JAMA, doi:10.1001/jama.2020.24865?utm_medium=email&utm_source=transaction
Zhang, Liu, Wang, SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19, J Hematol Oncol, doi:10.1186/s13045-020-00954-7?utm_medium=email&utm_source=transaction
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop